OmniAb, Inc. reports developments tied to its antibody discovery technology platform, partner pipeline and licensing model. The company licenses discovery research technology to pharmaceutical, biotechnology and academic partners, using engineered transgenic animals, Biological Intelligence™, computational antigen design, immunization methods, high-throughput single B-cell screening and sequencing-data mining to identify human antibody and target-binding protein candidates.
Recurring news includes quarterly financial results, partner program updates, new license agreements, milestone and royalty revenue, and technology launches such as OmniUltra™ and the xPloration® partner access program. Company updates also cover clinical and commercial progress of OmniAb-derived partnered programs, investor conference participation and corporate presentations focused on antibody discovery applications.
OmniAb (NASDAQ: OABI) will report its third-quarter 2026 financial results before U.S. financial markets open on October 30, 2026.
The results cover the three and nine months ended September 30, 2026. A conference call discussing the results and business updates will begin that day at 8:00 a.m. Eastern time (5:00 a.m. Pacific time). A live and replay webcast with slides will be available.
OmniAb (NASDAQ: OABI) outlined xPloration commercial expansion and revenue expectations, highlighted its partner pipeline, and introduced OmniTides at Investor & Analyst Day.
Beginning in October 2026, xPloration will be available for purchase by all customers, expanding beyond the Partner Access Program launched in 2025. OmniAb expects platform revenue of $2 million to $3 million in 2026, doubling in 2027 and doubling again in 2028, with revenue streams from instruments and related consumables.
Based on partner disclosures, OmniAb sees potential for primary completion of as many as 19 clinical trials evaluating OmniAb-derived drugs during the remaining months of 2026 and in 2027. Its partnerships include contracted potential downstream milestones and royalties. The new OmniTides peptide discovery offering uses the OmniUltra transgenic chicken platform, with peptide manufacturing available through qualified contract research organizations.
OmniAb (OABI) will host an Investor & Analyst Day on October 6, 2026, at 8 a.m. PT / 11 a.m. ET at its corporate headquarters in Emeryville, California, with both in-person and virtual participation available.
The event will include presentations from the executive leadership team covering corporate updates, select partner programs, the xPloration® platform, technology innovations and a Q&A session, as well as on-site demonstrations of the xPloration platform and laboratory tours for in-person attendees.
OmniAb (NASDAQ: OABI)/b) announced that management will participate in two investor conferences: the on Wednesday, September 9, 2026 at Nasdaq Headquarters in San Francisco, and the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at the Lotte New York Palace Hotel in New York City. Management plans to present a brief corporate overview and hold one-on-one meetings with investors at both events; interested investors are directed to contact the conference organizers or email investor relations.
OmniAb (NASDAQ: OABI) raised its full-year 2026 cash and cash equivalents guidance following recent technology licensing activity. The company now expects to end 2026 with $49 million to $53 million in cash and cash equivalents, compared with its prior range of $37 million to $41 million.
Management attributed the improved outlook to recent business development and licensing activity and indicated that partnerships using OmniAb’s discovery research technologies are expanding in scope and depth. Leadership reiterated a focus on leveraging its technology suite and partner ecosystem to support growth and long-term value creation.
OmniAb (NASDAQ: OABI) announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel discovery program. The partnership will use OmniAb’s technology platform and ion channel discovery and screening expertise to support Lilly’s efforts to develop next-generation therapeutics.
According to OmniAb, the company will receive an upfront payment and is eligible for up to $370 million in research, development and commercial milestone payments, plus tiered royalties on global net sales for any resulting products. The specific therapeutic target and modality for the ion channel program remain undisclosed.
OmniAb (NASDAQ: OABI) reported second quarter 2026 revenue of $13.4 million, up from $3.9 million a year earlier, driven mainly by milestone revenue and growth in ion channel services and xPloration instrument and consumable sales. Q2 2026 net loss narrowed to $5.9 million ($0.05/share) from $15.9 million ($0.15/share).
For the first half of 2026, revenue was $27.8 million versus $8.1 million in 2025, with net loss reduced to $13.6 million from $34.1 million. OmniAb ended June 30, 2026 with $52.0 million in cash, cash equivalents and short‑term investments.
The company raised 2026 guidance, now expecting revenue of $32–$36 million and year‑end cash of $37–$41 million. It now guides GAAP costs and operating expenses to $84–$88 million and non‑GAAP cash costs and operating expenses to $51–$55 million, and continues to expect a ~0% effective tax rate.
Business updates included new license agreements with EnRosa Therapeutics and argenx, 110 active partners and 425 active programs (including 34 in clinical development or commercialization), multiple partner‑reported clinical advances, and the appointment of Amechi Nwachuku as Executive Vice President and Chief Operating Officer to lead xPloration strategy and operations.
OmniAb (NASDAQ: OABI) announced it will release financial results for the three and six months ended June 30, 2026, after U.S. market close on Thursday, August 6, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern time (1:30 p.m. Pacific) to discuss second quarter 2026 results and provide business updates.
OmniAb (NASDAQ: OABI) has appointed Amechi Nwachuku as Executive Vice President and Chief Operating Officer, a newly created role effective immediately. He will lead strategy, operations and commercial maximization for xPloration, OmniAb’s proprietary high-throughput single B-cell screening platform.
Nwachuku brings over 25 years of global life sciences tools experience, including senior commercial leadership roles at Thermo Fisher Scientific, Danaher’s SCIEX and Beckman Coulter Diagnostics, as well as positions at Johnson & Johnson Diabetes Care, Bayer and McKinsey. OmniAb’s CEO highlighted xPloration as a complement to the company’s antibody discovery technology licensing business and a potential driver of diversified future revenue streams.
OmniAb (NASDAQ: OABI) reported Q1 2026 revenue of $14.4 million versus $4.2 million a year earlier and a net loss of $7.7 million ($0.06/share). The company raised full‑year 2026 revenue guidance to $28–$33 million and now expects year‑end cash of $33–$38 million.
Q1 cash costs were $12.3 million. OmniAb reported 107 active partners, 409 active programs and 32 programs in clinical development or commercialization. Management highlighted multiple partner clinical readouts due in 2026–2027.